SS Innovations International Inc. has announced its intention to submit a De Novo application for regulatory approval to market the SSi Mantra Surgical Robotic System to the U.S. Food and Drug Administration by the end of July 2025. This move is part of the company's efforts to expand its reach and make robotic surgery more accessible globally. Concurrently, SS Innovations is also pursuing a European Union CE marking certification, which they aim to obtain as soon as late 2025. These regulatory endeavors reflect the company's commitment to democratizing access to advanced surgical technologies and expanding its market presence beyond its current installations in India and six other countries.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.